Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 1.00 |
| ▸ | MAX | P61244 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.77 |
| ▸ | CRHBP | P24387 | 2/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.68 |
| ▸ | NAT1 | P18440 | 5/20 | 0.66 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346693 | 1.00 | MYC (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL10042186 | 1.00 | MYC (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL4051343 | 0.89 | NPC1 (0.79) | MYCMAXNPC1RAB9ACISD1 | |
| SCHEMBL4051348 | 0.89 | NPC1 (0.79) | MYCMAXNPC1RAB9ACISD1 | |
| SCHEMBL2539569 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL2539566 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL2539573 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL27412991 | 0.85 | MYC (0.74) | MYCMAXNPC1RAB9ACRHBP | |
| SCHEMBL8172749 | 0.84 | MYC (0.73) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL8172752 | 0.84 | MYC (0.73) | MYCMAXNPC1RAB9AIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | claimed |
| WO-2013163454-A2 | PSYLLID ATTRACTANTS AND THEIR USES | INSCENT, INC. (US) | 2013-10-31 | — | — | WO | claimed |
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | claimed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | claimed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | claimed |
| US-12599678-B2 | Methods and compositions for genomic integration | CREATE MEDICINES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250250584-A1 | METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION | CREATE MEDICINES, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12319925-B2 | Methods and compositions for genomic integration | MYELOID THERAPEUTICS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| CN-119818684-A | Application of ILDR A inhibitor in preparation of hepatocellular carcinoma drugs | 中国科学技术大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-7872027-B2 | Low molecular weight Myc-max inhibitors | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010083404-A2 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2007098010-A2 | IMPROVED LOW MOLECULAR WEIGHT MYC-MAX INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | UNIVERSITY OF PITTSBURGH (US) | 2007-08-30 | — | — | US | disclosed |
| US-7026343-B2 | Pharmacologic inhibition of Myc function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-19 | — | — | US | disclosed |
| WO-2003105759-A2 | PHARMACOLOGIC INHIBITION OF MYC FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034060-A1 | Pharmacologic inhibition of Myc function | MYCBP, MYC, MYCBP2 | MYC 2/4885MAX 5/4885NPC1 2624/4885 |
| US-12599678-B2 | Methods and compositions for genomic integration | RNGTT, UPF1, LNPEP | MYC 39/4885MAX 252/4885NPC1 323/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | MYC 2759/4885MAX 4299/4885NPC1 781/4885 |
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | MYC, MYCBP, MAX | MYC 1/4885MAX 3/4885NPC1 3276/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | MYC 6/4885MAX 1556/4885NPC1 1656/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | MYC 12/4885MAX 2554/4885NPC1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.